Patrick Bryant's Avatar

Patrick Bryant

@patrickbryant1.bsky.social

Assistant Professor at Stockholm University. Dedicated Scientist.

58 Followers  |  26 Following  |  13 Posts  |  Joined: 25.05.2025  |  1.764

Latest posts by patrickbryant1.bsky.social on Bluesky

Preview
GitHub - patrickbryant1/EvoBind: In silico directed evolution of peptide binders with AlphaFold In silico directed evolution of peptide binders with AlphaFold - patrickbryant1/EvoBind

This is the first study from my lab - providing the first PoC for both linear and cyclic untargeted binder design! EvoBind is available here: github.com/patrickbryan...

22.07.2025 11:23 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image

Our study where we develop EvoBind2: Design of linear and cyclic peptide binders from protein sequence information is now published! www.nature.com/articles/s42...

22.07.2025 11:23 β€” πŸ‘ 3    πŸ” 2    πŸ’¬ 1    πŸ“Œ 0

Cool! Congrats @proteinator.bsky.social πŸŽ‰

17.07.2025 05:49 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

We have much more coming in this space where we can identify target interfaces and inhibit the interactions - all using protein structure prediction!

06.07.2025 08:02 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Now published: our study on human-pathogen protein-protein interactions! We identify 30 interactions with an expected TM-score β‰₯0.9, tripling the structural coverage in these networks. One novel interaction was validated with mass spectrometry. journals.plos.org/ploscompbiol...

06.07.2025 08:02 β€” πŸ‘ 4    πŸ” 0    πŸ’¬ 2    πŸ“Œ 0
Post image

Our latest work is out: we designed dual GLP1R/GCGR agonistsβ€”cyclic peptides that activate both metabolic receptors, entirely from sequence alone.
This has never been done before. www.biorxiv.org/content/10.1...

09.06.2025 07:00 β€” πŸ‘ 5    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

You can also design in Colab now: colab.research.google.com/github/patri...

27.05.2025 12:40 β€” πŸ‘ 8    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0

The WT binder is 1.8 uM which means that we create as good binders but with new modes of binding for a target where these NCAA interactions are completely unknown 😎

25.05.2025 20:04 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Thanks! We will release a lot of new tech this year - stay tuned! We are only in the beginning of protein design I think

25.05.2025 20:02 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Science Cast Increase your recognition in the scientific world with short video-casts

There is also an audio summary generated by Science Cast here: sciencecast.org/casts/4kj8lr...

25.05.2025 14:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Just like we have used EvoBind to e.g. create functional HIV inhibitors in a single shot (biorxiv.org/content/10.1...) we can now do this with an expanded vocabulary to have more chemical possibilities and avoid e.g. immune recognition and degradation

25.05.2025 14:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

RareFold supports 49 different AAs.
The 20 regular, and 29 rare ones: MSE, TPO, MLY, CME, PTR, SEP,SAH, CSO, PCA, KCX, CAS, CSD, MLZ, OCS, ALY, CSS, CSX, HIC, HYP, YCM, YOF, M3L, PFF, CGU,FTR, LLP, CAF, CMH, MHO.
You can simply specify which you want to use and design!

25.05.2025 14:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 2    πŸ“Œ 0
Post image

Happy to release our breakthrough AI-model: RareFold, which predicts and designs proteins with noncanonical AAs. With EvoBindRare, we designed linear & cyclic peptide binders with high affinity & novel binding modes, wet lab validated.

πŸ“„ biorxiv.org/content/10.1...
πŸ’» github.com/patrickbryan...

25.05.2025 14:11 β€” πŸ‘ 19    πŸ” 4    πŸ’¬ 2    πŸ“Œ 1

@patrickbryant1 is following 20 prominent accounts